<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322461</url>
  </required_header>
  <id_info>
    <org_study_id>2020-3436</org_study_id>
    <nct_id>NCT04322461</nct_id>
  </id_info>
  <brief_title>Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population</brief_title>
  <acronym>PARKA</acronym>
  <official_title>Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two months intervention in which two groups of cognitive disorders, Parkinson and&#xD;
      Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with&#xD;
      supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and&#xD;
      after the intervention, along with endocannabinoids plasma concentrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>2 months, evaluation before and after intervention</time_frame>
    <description>Measure of cognition with CANTAB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ketones</measure>
    <time_frame>2 months, evaluation before and after intervention</time_frame>
    <description>Measurement of ketones concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endocannabinoids</measure>
    <time_frame>2 months, evaluation before and after intervention</time_frame>
    <description>Endocannabinoids plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Betaquik MCT supplement</intervention_name>
    <description>50g/day divided in 3. Breakfast, lunch and dinner</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Parkinson disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alzheimer's or parkinson disease diagnostic&#xD;
&#xD;
          -  Stable medication associated with the disease&#xD;
&#xD;
          -  Able to consent&#xD;
&#xD;
          -  Presence of an accompanying person for the first and last visit.&#xD;
&#xD;
          -  Ability to read and talk in French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MMSE &lt; 20&#xD;
&#xD;
          -  MCT or coconut oil supplementation&#xD;
&#xD;
          -  Coconut allergy&#xD;
&#xD;
          -  Cannabis, THC or CBD consumption&#xD;
&#xD;
          -  Excessive alcohol consumption&#xD;
&#xD;
          -  Physical activity 3x/week&#xD;
&#xD;
          -  Presence of an metallic object in the body&#xD;
&#xD;
          -  Impossibility to lay in dorsal decubitus for 40 minutes&#xD;
&#xD;
          -  Cardiac disease&#xD;
&#xD;
          -  Any uncontrolled disease that could interfer with the project.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Cunnane, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie St-Pierre, M.Sc.</last_name>
    <phone>819-780-2220</phone>
    <phone_ext>45286</phone_ext>
    <email>valerie.R.st-pierre@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mélanie Fortier, M.Sc.</last_name>
    <phone>819-80-2220</phone>
    <phone_ext>45252</phone_ext>
    <email>melanie.fortier2@usherbrooke.ca</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Parkinson</keyword>
  <keyword>Ketones</keyword>
  <keyword>medium chain triglycerides</keyword>
  <keyword>cognition</keyword>
  <keyword>brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

